[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Cardinal Health 200, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":119},{"warningLetters":4,"total":118},[5,31,51,72,98],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1507,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-04-25T16:50:00Z\">04\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-24T04:00:00Z\">04\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcardinal-health-679404-04242024\">Cardinal Health\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steve Mason\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cardinal Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7000 Dublin Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dublin\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>43017\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 679404\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 24, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mason:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm Cardinal Health 200, LLC., located at 3651 Birchwood Dr., Waukegan, Illinois 60085 on December 11-20, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is an importer \u002Fown label distributor of the Monoject™ Luer-lock tip syringes, intended to inject fluids into or withdraw fluids from the body, and the Monoject™ Enteral Feeding Syringes, intended for use to deliver fluid, feeding, or medications to a patient’s feeding tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received responses from you dated January 12, 2024, and April 10, 2024, concerning our investigators observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to the noted violations and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>1. The United States Food and Drug Administration (FDA) has learned that your firm is marketing convenience kits that include certain piston syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. These devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Specifically, the convenience kits your firm markets in the United States include 3 mL, 10 mL, and 20 mL piston syringes and control syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. The only Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe cleared under K103830 is their 5cc Luer Lock, and no other size piston syringes were included under K103830. Based on FDA's evaluation of K103830 and your firm's activities, there is evidence that your firm is engaged in the distribution of Jiangsu Shenli syringes for use within the United States, included as part of convenience kits, with substantially different technological characteristics. In particular, FDA’s evaluation revealed that these kits include Jiangsu Shenli syringes in sizes other than 5 mL and also include control syringes. The inclusion of these syringes whose specifications were not included or otherwise reviewed under the conditions of clearance in K103830, constitutes a significant change or modification in design that could significantly alter the safety or effectiveness of the finished kit product. Specifically, changing the volume of the syringe and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing and a leaking device.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fp>\n\n\u003Cp>Specifically, our inspection found that your Procedure “QS00015426, Manufacturing Concept Sample Inspection” Rev. 4 employed by your firm to outline product requirements, confirm purchased products have met these requirements, and conduct supplier qualification activities, has not been adequately established. Your firm’s procedure does not require that data to demonstrate product requirements are met is reviewed and evaluated during supplier qualification activities. Per your product requirements document “Needle and Syringe PRD” the product requirements for these devices included, but were not limited to, those in ISO Standard 7886-1:2017 “\u003Cem>Sterile hypodermic syringes for single use - Part 1: Syringes for Manual Use\u003C\u002Fem>”. The ISO Standard 7886-1 relates specifically to the manual use of the syringes and includes product specifications such as limits for acidity and alkalinity, extractable metals, and dimensions. The review of your supplier qualification activities disclosed that specific product requirements required under the standard such as dimensions, limits for acidity and alkalinity, and extractable metals were not established in the product requirements document. Furthermore, no data was received from the supplier and\u002For evaluated at the time of supplier qualification to ensure that other product requirements included in the PRD document were met. In addition, you were not able to produce data to support the use of your Monoject Syringes for compatible use with infusion pumps. In particular, on September 20, 2023 and December 28, 2023, your firm initiated recalls for the Cardinal Health Monoject sterile Syringe Luer-Lock Tip Soft Packs (1, 3, 6, 12, 20, 35 and 60 mL) and Cardinal Health Monoject sterile Enteral Syringes with ENFit connection (1, 3, 6, 12, 35, and 60 mL) due to a change in manufacturing that resulted in different product dimensions, which can lead to recognition and compatibility issues when used with syringe pumps, patient-controlled analgesia (PCA) pumps, and enteral syringe feeding pumps.\u003C\u002Fp>\n\n\u003Cp>Your responses dated January 12, 2024, and April 10, 2024, indicated that you have opened CAPA-CRP-03163 (also referenced as CAPA QE-00303) to address this observation and that the process will be revised to demonstrate product requirements are met, reviewed, and evaluated during supplier qualification activities. Your response indicates you will revise and update your procedure QS00015441, Private Brand Procedure, and revise your Technical Guide template adding detail and greater focus on customer needs and clinical requirements. You will perform a product audit prior to initial release to verify requirements are met, validations meet requirements, and product lot testing and release acceptance process are statistically based and meets requirements. You will repurpose and revise your procedure QS00015426, Manufacturing Concept Sample Inspection Process, and revise the Q00014202, Private Brand Supplier Quality Agreement Template. Training will be conducted. In addition, you will conduct a systemic review of in-process and completed Private Brand Conversions, from the past three (3) years.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. FDA acknowledges that your responses to date state that your firm has conducted a variety of updates to its internal processes and associated trainings, including, but not limited to, those related to QS00015441 (Private Brand Technical Procedure), QS00015426 (Manufacturing Concept Sample Review), and QS00014202 (Private Brand Supplier Quality Agreement (SQA) Template). However, your corrective actions have not yet been evaluated for effectiveness. A follow-up inspection will need to verify the implementation and the effectiveness of your planned corrective actions.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>During our inspection, FDA determined that your firm was engaged in the self-manufacturing of 3, 6, 20, 35, and 60mL Monoject Standard Luer Lock Syringes based on specifications cleared under K945715. Your firm then switched to overseas manufacturing with Jiangsu Caina Medical Co. Ltd. to produce the same size range of syringes branded as Cardinal Health Monject Syringes and based on specifications cleared under K113091. FDA is aware that your firm’s self-manufactured syringes were validated by infusion pump manufacturers for use with their devices, that as of December 2023 your firm’s syringes were collectively marketed and advertised as compatible for use with infusion pumps, and that since switching to overseas manufacturing there have been increases in reported syringe safety issues regarding syringe\u002Finfusion pump compatibility resulting in your firm’s ongoing syringe recalls. Further, during our inspection, you were unable to provide documented rationales, assessments or evaluations during the inspection concerning any impact of pump compatibility claims on regulatory submissions for the Cardinal Health Monoject Syringe product family. You also stated during the inspection that existing procedures at the time failed to ensure that this assessment was conducted and documented. No evidence was produced during the inspection describing evaluation of infusion pump compatibility intended use claims for the Cardinal Health Monoject Syringes by you or Jiangsu Caina Medical Co. Ltd, that you conducted any product testing related to the use of Monoject syringes with infusion pumps, or that you informed infusion pump manufacturers of the specification changes to the 3, 6, 20, 35 and 60 ml Monoject Standard Luer Lock Syringes. FDA acknowledges that your firm has ceased using marketing materials regarding compatibility with infusion pumps, and that your firm has taken several actions to revise and review its internal policies regarding device marketing. However, to date FDA has not received information regarding the effectiveness of these actions or what additional actions your firm is taking or plans to take regarding the use of these syringes with infusion pumps, especially in light of known patient safety risks regarding syringe incompatibility with infusion pumps. Accordingly, we request that you provide to us in writing what actions your firm has taken and plans to take regarding these products with respect to their use with infusion pumps.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 679404\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at 612-758-7210 or Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nJames Hildreth\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health Operations (OMDRHO)\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nKellie B. Kelm, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT 3: Office of Gastrorenal, ObGyn, General Hospital, and Urology\u003Cbr>\nDevices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteve Mason\n\nRecipient Title\n\nPresident\u002FCEO\n\nCardinal Health\n\n7000 Dublin Place\n\nDublin, OH 43017\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 679404\n\nApril 24, 2024\n\nDear Mr. Mason:\n\nDuring an inspection of your firm Cardinal Health 200, LLC., located at 3651 Birchwood Dr., Waukegan, Illinois 60085 on December 11-20, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is an importer \u002Fown label distributor of the Monoject™ Luer-lock tip syringes, intended to inject fluids into or withdraw fluids from the body, and the Monoject™ Enteral Feeding Syringes, intended for use to deliver fluid, feeding, or medications to a patient’s feeding tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received responses from you dated January 12, 2024, and April 10, 2024, concerning our investigators observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to the noted violations and any additional responses will be reviewed as part of your warning letter response.\n\nUnapproved Device Violations\n\n1. The United States Food and Drug Administration (FDA) has learned that your firm is marketing convenience kits that include certain piston syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. These devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\n\nSpecifically, the convenience kits your firm markets in the United States include 3 mL, 10 mL, and 20 mL piston syringes and control syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. The only Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe cleared under K103830 is their 5cc Luer Lock, and no other size piston syringes were included under K103830. Based on FDA's evaluation of K103830 and your firm's activities, there is evidence that your firm is engaged in the distribution of Jiangsu Shenli syringes for use within the United States, included as part of convenience kits, with substantially different technological characteristics. In particular, FDA’s evaluation revealed that these kits include Jiangsu Shenli syringes in sizes other than 5 mL and also include control syringes. The inclusion of these syringes whose specifications were not included or otherwise reviewed under the conditions of clearance in K103830, constitutes a significant change or modification in design that could significantly alter the safety or effectiveness of the finished kit product. Specifically, changing the volume of the syringe and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing and a leaking device.\n\nYour firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes.\n\nQuality System Regulation Violations\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\n\nSpecifically, our inspection found that your Procedure “QS00015426, Manufacturing Concept Sample Inspection” Rev. 4 employed by your firm to outline product requirements, confirm purchased products have met these requirements, and conduct supplier qualification activities, has not been adequately established. Your firm’s procedure does not require that data to demonstrate product requirements are met is reviewed and evaluated during supplier qualification activities. Per your product requirements document “Needle and Syringe PRD” the product requirements for these devices included, but were not limited to, those in ISO Standard 7886-1:2017 “Sterile hypodermic syringes for single use - Part 1: Syringes for Manual Use”. The ISO Standard 7886-1 relates specifically to the manual use of the syringes and includes product specifications such as limits for acidity and alkalinity, extractable metals, and dimensions. The review of your supplier qualification activities disclosed that specific product requirements required under the standard such as dimensions, limits for acidity and alkalinity, and extractable metals were not established in the product requirements document. Furthermore, no data was received from the supplier and\u002For evaluated at the time of supplier qualification to ensure that other product requirements included in the PRD document were met. In addition, you were not able to produce data to support the use of your Monoject Syringes for compatible use with infusion pumps. In particular, on September 20, 2023 and December 28, 2023, your firm initiated recalls for the Cardinal Health Monoject sterile Syringe Luer-Lock Tip Soft Packs (1, 3, 6, 12, 20, 35 and 60 mL) and Cardinal Health Monoject sterile Enteral Syringes with ENFit connection (1, 3, 6, 12, 35, and 60 mL) due to a change in manufacturing that resulted in different product dimensions, which can lead to recognition and compatibility issues when used with syringe pumps, patient-controlled analgesia (PCA) pumps, and enteral syringe feeding pumps.\n\nYour responses dated January 12, 2024, and April 10, 2024, indicated that you have opened CAPA-CRP-03163 (also referenced as CAPA QE-00303) to address this observation and that the process will be revised to demonstrate product requirements are met, reviewed, and evaluated during supplier qualification activities. Your response indicates you will revise and update your procedure QS00015441, Private Brand Procedure, and revise your Technical Guide template adding detail and greater focus on customer needs and clinical requirements. You will perform a product audit prior to initial release to verify requirements are met, validations meet requirements, and product lot testing and release acceptance process are statistically based and meets requirements. You will repurpose and revise your procedure QS00015426, Manufacturing Concept Sample Inspection Process, and revise the Q00014202, Private Brand Supplier Quality Agreement Template. Training will be conducted. In addition, you will conduct a systemic review of in-process and completed Private Brand Conversions, from the past three (3) years.\n\nThe adequacy of your firm’s response cannot be determined at this time. FDA acknowledges that your responses to date state that your firm has conducted a variety of updates to its internal processes and associated trainings, including, but not limited to, those related to QS00015441 (Private Brand Technical Procedure), QS00015426 (Manufacturing Concept Sample Review), and QS00014202 (Private Brand Supplier Quality Agreement (SQA) Template). However, your corrective actions have not yet been evaluated for effectiveness. A follow-up inspection will need to verify the implementation and the effectiveness of your planned corrective actions.\n\nIn addition, we offer the following comment:\n\nDuring our inspection, FDA determined that your firm was engaged in the self-manufacturing of 3, 6, 20, 35, and 60mL Monoject Standard Luer Lock Syringes based on specifications cleared under K945715. Your firm then switched to overseas manufacturing with Jiangsu Caina Medical Co. Ltd. to produce the same size range of syringes branded as Cardinal Health Monject Syringes and based on specifications cleared under K113091. FDA is aware that your firm’s self-manufactured syringes were validated by infusion pump manufacturers for use with their devices, that as of December 2023 your firm’s syringes were collectively marketed and advertised as compatible for use with infusion pumps, and that since switching to overseas manufacturing there have been increases in reported syringe safety issues regarding syringe\u002Finfusion pump compatibility resulting in your firm’s ongoing syringe recalls. Further, during our inspection, you were unable to provide documented rationales, assessments or evaluations during the inspection concerning any impact of pump compatibility claims on regulatory submissions for the Cardinal Health Monoject Syringe product family. You also stated during the inspection that existing procedures at the time failed to ensure that this assessment was conducted and documented. No evidence was produced during the inspection describing evaluation of infusion pump compatibility intended use claims for the Cardinal Health Monoject Syringes by you or Jiangsu Caina Medical Co. Ltd, that you conducted any product testing related to the use of Monoject syringes with infusion pumps, or that you informed infusion pump manufacturers of the specification changes to the 3, 6, 20, 35 and 60 ml Monoject Standard Luer Lock Syringes. FDA acknowledges that your firm has ceased using marketing materials regarding compatibility with infusion pumps, and that your firm has taken several actions to revise and review its internal policies regarding device marketing. However, to date FDA has not received information regarding the effectiveness of these actions or what additional actions your firm is taking or plans to take regarding the use of these syringes with infusion pumps, especially in light of known patient safety risks regarding syringe incompatibility with infusion pumps. Accordingly, we request that you provide to us in writing what actions your firm has taken and plans to take regarding these products with respect to their use with infusion pumps.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 679404 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at 612-758-7210 or Demetria.Lueneburg@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nJames Hildreth\n\nActing Program Division Director\n\nOffice of Medical Device and Radiological Health Operations (OMDRHO)\n\nDivision 2 Central\n\n\u002FS\u002F\n\nKellie B. Kelm, Ph.D.\n\nActing Office Director\n\nOHT 3: Office of Gastrorenal, ObGyn, General Hospital, and Urology\n\nDevices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Cardinal Health","cardinal-health-679404-04242024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcardinal-health-679404-04242024","2026-10-26T08:08:11.196227+00:00","Warning Letter","Issued","2024-04-25","679404","Medical Devices","Steve Mason","2026-08-20T00:09:49.056+00:00","VIA UNITED PARCEL SERVICE","2024-04-24",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":48,"body_fetched_at":49,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1472,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2024-05-13T13:20:00Z\">05\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-09T04:00:00Z\">05\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcue-health-inc-675673-05092024\">Cue Health, Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Clint Sever\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cue Health, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4980 Carroll Canyon Rd Ste 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121-1736\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS# 675673\u003C\u002Fp>\n\n\u003Cp>May 9, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Sever:\u003C\u002Fp>\n\n\u003Cp>The Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Cue Health, Inc. (“Cue Health”, “you”, or “your firm”) located at 4980 Carroll Canyon Rd Ste 100, San Diego, CA 92121-1736 on 10 dates between October 17, 2023 and November 3, 2023. During this inspection, the investigator determined that your firm markets and distributes the Cue Health COVID-19 Test and the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>FDA authorized the Cue Health COVID-19 Test under EUA200248 on June 10, 2020, granted revisions to the authorized labeling on August 20, 2020, and subsequently re-issued the emergency use authorization (EUA) in its entirety on March 26, 2021. The COVID-19 Test is authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in direct anterior nasal swabs or in previously collected anterior nasal specimens in viral transport media from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19. Emergency use of this test is limited to authorized laboratories.\u003C\u002Fp>\n\n\u003Cp>FDA also authorized the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use under EUA210180 on March 5, 2021. The COVID-19 Test for Home and Over The Counter (OTC) Use is a molecular diagnostic test for the qualitative detection of nucleic acid from SARS-CoV-2 in anterior nasal (nasal) swab specimens collected with the Cue Sample Wand. The test is intended for use in adults (self-swabbing) or children ≥2 years of age (swabbed by an adult) with or without symptoms or other epidemiological reasons to suspect COVID-19 and is authorized for non-prescription home use.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that you are not complying with the following Conditions of Authorization in the Letters of Authorization for EUA200248 and EUA210180. For example:\u003C\u002Fp>\n\n\u003Cp>1. Evidence obtained during the inspection demonstrated that your firm implemented several changes to your EUA-authorized devices and implemented those changes without authorization from FDA pursuant to the Conditions of Authorization. For example, documentation showed that on October 23, 2023, your firm implemented change order CP-4166 to both EUA-authorized COVID-19 devices. As part of this change order, it appears that you implemented changes in the formulation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which serves as a substrate for the reaction and is responsible for generating the signal to detect the presence of the target, modified the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and updated the device firmware to add functionality to detect failure of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and added a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to modify the raw electrochemical signal from the reaction to correct for observed temperature-based signal differences, and that these changes were implemented after your firm received an EUA-authorization for your devices and in the absence of notification or FDA concurrence. These modifications may negatively impact the stability of the devices, resulting in failure earlier than the 9 months claimed on the product labeling, as documents TS0496 and TS0555 observed during our inspection indicated that these modifications were implemented with the intent to affect overall device performance and in particular device stability.\u003C\u002Fp>\n\n\u003Cp>Pursuant to Condition K (EUA200248) and Condition L (EUA210180), “You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling and shall not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)\u002FOffice of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)\u002FOffice of Product Evaluation and Quality (OPEQ)\u002FCenter for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation”. CDRH has reviewed the information collected during the inspection and has determined that your firm has failed to submit a request for the changes identified above to your devices for FDA review and obtain FDA authorization prior to implementation. CDRH has determined that these are significant modifications, as they have a strong likelihood to impact the performance of the device due to significant changes to reagent formulations and device design of these devices. Therefore, you are not permitted to distribute the modified Cue Health COVID-19 Test or Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until you receive authorization.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> We request that you take immediate action to cease the sale and distribution of your Cue Health COVID-19 Test and your Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until such time that you have received FDA concurrence for the modifications you have made to your tests pursuant to your respective conditions of authorization.\u003C\u002Fp>\n\n\u003Cp>2. Pursuant to Condition M (EUA200248) and Condition N (EUA210180), your firm is required to have lot release activities to ensure that the product released meets the clinical and analytical performance claimed in the authorized labeling. CDRH has reviewed the information collected during the inspection and has determined that you are not in compliance with Conditions M and N of the respective EUAs. For example, inspection of your firm’s document “QC2900005 Cartridge Assembly, COVID-19, Pouched” (Revision 12) effective since August 31, 2022, has identified that your firm is using an Acceptable Quality Level (AQL) for functional testing of the COVID-19 cartridges when testing against negative panels which would allow for a failure rate for commercially released product to be higher than the stated Negative Percent Agreement (NPA) clinical performance claims for the EUA devices. Your EUA-authorized devices have a claimed performance of 99.1% Negative Percent Agreement (NPA). However, your lot release activities indicate that you are using an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% which is not sufficient to ensure that tests released for distribution have the analytical and clinical performance claimed in the authorized labeling. The release of products that fail to meet their claimed performance could lead to an increase in false positive results.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at ORADevices3FirmResponse@fda.hhs.gov and CDRHWarningLetterResponse@fda.hhs.gov. Refer to CMS #675673 when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Y. Perkins, Compliance Officer, at (619) 941-3763 or shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nShari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney Lias\u003Cbr>\nActing Director\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that a device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), if it does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). A device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), if a firm does not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA [21 CFR 807.81(b)].\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Clint Sever\n\nRecipient Title\n\nChief Executive Officer\n\nCue Health, Inc.\n\n4980 Carroll Canyon Rd Ste 100\n\nSan Diego, CA 92121-1736\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 675673\n\nMay 9, 2024\n\nDear Mr. Sever:\n\nThe Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Cue Health, Inc. (“Cue Health”, “you”, or “your firm”) located at 4980 Carroll Canyon Rd Ste 100, San Diego, CA 92121-1736 on 10 dates between October 17, 2023 and November 3, 2023. During this inspection, the investigator determined that your firm markets and distributes the Cue Health COVID-19 Test and the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nFDA authorized the Cue Health COVID-19 Test under EUA200248 on June 10, 2020, granted revisions to the authorized labeling on August 20, 2020, and subsequently re-issued the emergency use authorization (EUA) in its entirety on March 26, 2021. The COVID-19 Test is authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in direct anterior nasal swabs or in previously collected anterior nasal specimens in viral transport media from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19. Emergency use of this test is limited to authorized laboratories.\n\nFDA also authorized the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use under EUA210180 on March 5, 2021. The COVID-19 Test for Home and Over The Counter (OTC) Use is a molecular diagnostic test for the qualitative detection of nucleic acid from SARS-CoV-2 in anterior nasal (nasal) swab specimens collected with the Cue Sample Wand. The test is intended for use in adults (self-swabbing) or children ≥2 years of age (swabbed by an adult) with or without symptoms or other epidemiological reasons to suspect COVID-19 and is authorized for non-prescription home use.\n\nOur inspection revealed that you are not complying with the following Conditions of Authorization in the Letters of Authorization for EUA200248 and EUA210180. For example:\n\n1. Evidence obtained during the inspection demonstrated that your firm implemented several changes to your EUA-authorized devices and implemented those changes without authorization from FDA pursuant to the Conditions of Authorization. For example, documentation showed that on October 23, 2023, your firm implemented change order CP-4166 to both EUA-authorized COVID-19 devices. As part of this change order, it appears that you implemented changes in the formulation of your (b)(4), which serves as a substrate for the reaction and is responsible for generating the signal to detect the presence of the target, modified the (b)(4) and updated the device firmware to add functionality to detect failure of (b)(4), and added a (b)(4) to modify the raw electrochemical signal from the reaction to correct for observed temperature-based signal differences, and that these changes were implemented after your firm received an EUA-authorization for your devices and in the absence of notification or FDA concurrence. These modifications may negatively impact the stability of the devices, resulting in failure earlier than the 9 months claimed on the product labeling, as documents TS0496 and TS0555 observed during our inspection indicated that these modifications were implemented with the intent to affect overall device performance and in particular device stability.\n\nPursuant to Condition K (EUA200248) and Condition L (EUA210180), “You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling and shall not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)\u002FOffice of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)\u002FOffice of Product Evaluation and Quality (OPEQ)\u002FCenter for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation”. CDRH has reviewed the information collected during the inspection and has determined that your firm has failed to submit a request for the changes identified above to your devices for FDA review and obtain FDA authorization prior to implementation. CDRH has determined that these are significant modifications, as they have a strong likelihood to impact the performance of the device due to significant changes to reagent formulations and device design of these devices. Therefore, you are not permitted to distribute the modified Cue Health COVID-19 Test or Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until you receive authorization.1 We request that you take immediate action to cease the sale and distribution of your Cue Health COVID-19 Test and your Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until such time that you have received FDA concurrence for the modifications you have made to your tests pursuant to your respective conditions of authorization.\n\n2. Pursuant to Condition M (EUA200248) and Condition N (EUA210180), your firm is required to have lot release activities to ensure that the product released meets the clinical and analytical performance claimed in the authorized labeling. CDRH has reviewed the information collected during the inspection and has determined that you are not in compliance with Conditions M and N of the respective EUAs. For example, inspection of your firm’s document “QC2900005 Cartridge Assembly, COVID-19, Pouched” (Revision 12) effective since August 31, 2022, has identified that your firm is using an Acceptable Quality Level (AQL) for functional testing of the COVID-19 cartridges when testing against negative panels which would allow for a failure rate for commercially released product to be higher than the stated Negative Percent Agreement (NPA) clinical performance claims for the EUA devices. Your EUA-authorized devices have a claimed performance of 99.1% Negative Percent Agreement (NPA). However, your lot release activities indicate that you are using an AQL of (b)(4)% which is not sufficient to ensure that tests released for distribution have the analytical and clinical performance claimed in the authorized labeling. The release of products that fail to meet their claimed performance could lead to an increase in false positive results.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\n\nYour firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at ORADevices3FirmResponse@fda.hhs.gov and CDRHWarningLetterResponse@fda.hhs.gov. Refer to CMS #675673 when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Y. Perkins, Compliance Officer, at (619) 941-3763 or shaquenta.perkins@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\n\nOffice of Regulatory Affairs\n\n\u002FS\u002F\n\nCourtney Lias\n\nActing Director\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n__________________________\n\n1 We note that a device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), if it does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). A device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), if a firm does not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA [21 CFR 807.81(b)].","Cue Health, Inc.","cue-health-inc-675673-05092024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcue-health-inc-675673-05092024","2026-10-26T08:08:19.781607+00:00","2024-05-13","675673","Mr. Clint Sever","2026-08-20T00:06:27.848+00:00","2024-05-09",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":18,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":57,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},1870,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:00:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-11T04:00:00Z\">09\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcvs-health-663246-09112023\">CVS Health\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Karen S. Lynch\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CVS Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>One CVS Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Woonsocket\u003C\u002Fspan>, \u003Cspan>RI\u003C\u002Fspan> \u003Cspan>02895\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Karen.Lynch@cvshealth.com\"> Karen.Lynch@cvshealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 11, 2023\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 663246\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Karen S. Lynch:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.cvs.com in July 2023. The FDA has observed that your website offers “CVS Health Pink Eye Relief Drops” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Your “CVS Health Pink Eye Relief Drops” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your product labeling, including on your website, your “CVS Health Pink Eye Relief Drops” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your product labeling, including on your website www.cvs.com, that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On the product webpage for “CVS Health Pink Eye Relief Drops,” https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fcvs-health-pink-eye-relief-drops-0-33-oz-prodid-1010883:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"Relieves •Redness •Burning •Watery discharge •Gritty sensation”\u003C\u002Fli>\n\t\u003Cli>“[T]emporarily relieve minor eye symptoms: •excessive watery (clear) discharge •sensation of grittiness •redness and burning”\u003C\u002Fli>\n\t\u003Cli>“CVS Health Pink Eye Drops is a homeopathic formula that stimulates the body’s ability to relieve redness, burning, watery discharge, and sensations of grittiness.”\u003C\u002Fli>\n\t\u003Cli>“When your eyes are dry, itching, or burning, it can be a big problem that you want relief from right away. These Irritated Eye Drops from CVS Health can provide you with the rapid relief you need . . . They are very helpful for relieving irritation, redness, burning, and dryness. The homeopathic formula is safe for use in the eyes and easy to apply . . . These drops are gentle enough for frequent use and even for use on children.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your “CVS Health Pink Eye Relief Drops” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for “CVS Health Pink Eye Relief Drops.” Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>We recognize that your “CVS Health Pink Eye Relief Drops” is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>Additionally, CVS is responsible for ensuring that the drug products it distributes are not adulterated. We understand that your “CVS Health Pink Eye Relief Drops” product is produced for CVS by a contract manufacturer, i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The significant violations of Current Good Manufacturing Practice (CGMP) requirements observed at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with respect to its manufacture of homeopathic ophthalmic products, are documented in the Agency’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> warning letter to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Under section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), drugs are deemed adulterated if they are not manufactured in conformance with CGMPs. The CGMP violations identified at \u003Cstrong>(b)(4)\u003C\u002Fstrong> caused all drug products manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong> to be adulterated. The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of an adulterated drug is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). Further, the receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. In addition, please note that unapproved new drugs are subject to refusal of admission into the United States, and such products may be subject to detention without physical examination. For more information about detention without physical examination, see Import Alert 66-41.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>cc:&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that your ophthalmic drug products utilize silver sulfate as a preservative. The Agency has significant concerns regarding the safety of silver sulfate for use as an ophthalmic preservative. Long term use of medicinal compounds containing silver may cause argyria, which is a blueish-gray discoloration of the skin and eyes that is irreversible. Additionally, granular deposits of silver in the conjunctiva and cornea may cause decreased night vision. Accordingly, we are concerned that your use of silver sulfate as a preservative in your ophthalmic products is inconsistent with 21 C.F.R. 200.50(b)(1), under which ophthalmic preservatives should be “suitable and harmless.”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKaren S. Lynch\n\nRecipient Title\n\nPresident & CEO\n\nCVS Health\n\nOne CVS Drive\n\nWoonsocket, RI 02895\n\nUnited States\n\nKaren.Lynch@cvshealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nSeptember 11, 2023\n\nRE: 663246\n\nDear Karen S. Lynch:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.cvs.com in July 2023. The FDA has observed that your website offers “CVS Health Pink Eye Relief Drops” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nYour “CVS Health Pink Eye Relief Drops” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.1\n\nBased on a review of your product labeling, including on your website, your “CVS Health Pink Eye Relief Drops” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your product labeling, including on your website www.cvs.com, that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\n\nOn the product webpage for “CVS Health Pink Eye Relief Drops,” https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fcvs-health-pink-eye-relief-drops-0-33-oz-prodid-1010883:\n\n\"Relieves •Redness •Burning •Watery discharge •Gritty sensation”\n\n“[T]emporarily relieve minor eye symptoms: •excessive watery (clear) discharge •sensation of grittiness •redness and burning”\n\n“CVS Health Pink Eye Drops is a homeopathic formula that stimulates the body’s ability to relieve redness, burning, watery discharge, and sensations of grittiness.”\n\n“When your eyes are dry, itching, or burning, it can be a big problem that you want relief from right away. These Irritated Eye Drops from CVS Health can provide you with the rapid relief you need . . . They are very helpful for relieving irritation, redness, burning, and dryness. The homeopathic formula is safe for use in the eyes and easy to apply . . . These drops are gentle enough for frequent use and even for use on children.”\n\nYour “CVS Health Pink Eye Relief Drops” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for “CVS Health Pink Eye Relief Drops.” Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nWe recognize that your “CVS Health Pink Eye Relief Drops” is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nAdditionally, CVS is responsible for ensuring that the drug products it distributes are not adulterated. We understand that your “CVS Health Pink Eye Relief Drops” product is produced for CVS by a contract manufacturer, i.e., (b)(4). The significant violations of Current Good Manufacturing Practice (CGMP) requirements observed at (b)(4), with respect to its manufacture of homeopathic ophthalmic products, are documented in the Agency’s (b)(4) warning letter to (b)(4). Under section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), drugs are deemed adulterated if they are not manufactured in conformance with CGMPs. The CGMP violations identified at (b)(4) caused all drug products manufactured by (b)(4) to be adulterated. The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of an adulterated drug is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Further, the receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. In addition, please note that unapproved new drugs are subject to refusal of admission into the United States, and such products may be subject to detention without physical examination. For more information about detention without physical examination, see Import Alert 66-41.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\ncc: (b)(4)\n\n___________________________\n\n1 We note that your ophthalmic drug products utilize silver sulfate as a preservative. The Agency has significant concerns regarding the safety of silver sulfate for use as an ophthalmic preservative. Long term use of medicinal compounds containing silver may cause argyria, which is a blueish-gray discoloration of the skin and eyes that is irreversible. Additionally, granular deposits of silver in the conjunctiva and cornea may cause decreased night vision. Accordingly, we are concerned that your use of silver sulfate as a preservative in your ophthalmic products is inconsistent with 21 C.F.R. 200.50(b)(1), under which ophthalmic preservatives should be “suitable and harmless.”","CVS Health","cvs-health-663246-09112023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcvs-health-663246-09112023","2026-10-26T08:08:20.505694+00:00","2023-09-12","663246","Drugs","Karen S. Lynch","2026-08-20T00:41:46.185+00:00","Via Email","2023-09-11",{"id":73,"raw":74,"subject":79,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":88,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":92,"issuing_office":78,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":96,"action_taken_date":97,"medical_device_id":19,"response_letter_date":19},256,[75,76,77,78,79,13,80,13],"\u003Ctime datetime=\"2026-03-24T04:00:00Z\">03\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F4u-health-720527-03172026\">4U Health\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Premarket Approval\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F4u-health-720527-06162026\">\u003Ctime datetime=\"2026-06-23T04:00:00Z\">06\u002F23\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-720527\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alfred Caminos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Founder and Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>4U Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>71 Lighthouse Road, Suite 220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hilton Head Island\u003C\u002Fspan>, \u003Cspan>SC\u003C\u002Fspan> \u003Cspan>29928\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@4uhealth.com\"> help@4uhealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 17, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-720527\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Alfred Caminos:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA or the Agency) has learned that your firm, 4U Health, is offering for sale in the United States a human immunodeficiency virus (HIV) serological diagnostic dried blood spot (DBS) card self-collection kit (hereinafter, your “HIV DBS card self-collection kit”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Under section 201(h)(1) of the FD&amp;C Act, 21 U.S.C. 321(h)(1), your HIV DBS card self-collection kit is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>FDA has reviewed your company’s website at www.4uhealth.com (last visited March 2026) and your firm’s responses to previous FDA correspondence. Based on our review of these materials, your firm offers its HIV DBS card self-collection kit for delivery to individuals and intends for these individuals to use the kit to self-collect DBS samples and ship those samples to laboratories for HIV testing. FDA has determined that your HIV DBS card self-collection kit is adulterated under section 501(f)(1)(B) of the FD&amp;C Act, 21 U.S.C. 351(f)(1)(B) because it does not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&amp;C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&amp;C Act, 21 U.S.C. 360j(g). Your HIV DBS card self-collection kit is also misbranded under section 502(o) the FD&amp;C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the agency, as required by section 510(k) of the FD&amp;C Act, 21 U.S.C. 360(k).\u003C\u002Fp>\u003Cp>FDA has not authorized your firm’s HIV DBS card self-collection kit for use in HIV serological diagnostic testing.\u003C\u002Fp>\u003Cp>In a letter dated March 31, 2025, FDA informed you that you appeared to be offering for sale and distributing your HIV serological diagnostic self-collection kits in a manner that may violate the FD&amp;C Act. In your response dated April 30, 2025, you assert that 4U Health “do[es] not sell self-collection testing kits,” and that 4U Health instead “facilitates access to professional medical services, including HIV testing.” You indicate that “[y]our physician consultants order” tests and “oversee the entire testing process.” And you state that the “service” you offer is “not intended to diagnose, treat, or cure any disease on its own,” as “[p]ositive results require confirmation and diagnosis by a licensed medical provider not affiliated with 4U Health.”\u003C\u002Fp>\u003Cp>Express statements on your firm’s website and in your April 30, 2025 response make clear that your firm is selling and distributing HIV serological diagnostic self-collection kits. For example, your website states that the kit “will arrive in plain packaging” and “contains everything you need to collect your home sample.” And your April 30, 2025 response acknowledges that your “at-home testing collection supplies” are “provided to [y]our clients for sample collection.” As explained above, because your firm’s HIV DBS card self-collection kit is a device that has not received FDA marketing authorization, the kit is adulterated and misbranded.\u003C\u002Fp>\u003Cp>Notably, this letter and the March 31, 2025 letter sent to your firm focus on your HIV serological diagnostic self-collection kits and are not intended to be a comprehensive list of potential issues with your firm’s products. Even if, as you say, any testing you conduct on samples is intended to provide only preliminary results, the kits you “source[] from independent distributors” and ship to customers for the purpose of sample collection by customers “at-home” (as stated in your April 30, 2025 response) are devices. Nor does the involvement of “physician consultants” in ordering any testing or interpreting any results mean that the collection kits you are shipping are not devices.\u003C\u002Fp>\u003Cp>Without appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your HIV DBS card self-collection kit. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We also note that there are FDA-approved over-the-counter HIV tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your HIV DBS card self-collection kit. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-720527\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nAlfred Caminos\n\nRecipient Title\n\nCo-Founder and Managing Director\n\n4U Health\n\n71 Lighthouse Road, Suite 220\n\nHilton Head Island, SC 29928\n\nUnited States\n\nhelp@4uhealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nMarch 17, 2026\nCBER 26-720527\nDear Alfred Caminos:\nThe United States Food and Drug Administration (FDA or the Agency) has learned that your firm, 4U Health, is offering for sale in the United States a human immunodeficiency virus (HIV) serological diagnostic dried blood spot (DBS) card self-collection kit (hereinafter, your “HIV DBS card self-collection kit”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under section 201(h)(1) of the FD&C Act, 21 U.S.C. 321(h)(1), your HIV DBS card self-collection kit is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nFDA has reviewed your company’s website at www.4uhealth.com (last visited March 2026) and your firm’s responses to previous FDA correspondence. Based on our review of these materials, your firm offers its HIV DBS card self-collection kit for delivery to individuals and intends for these individuals to use the kit to self-collect DBS samples and ship those samples to laboratories for HIV testing. FDA has determined that your HIV DBS card self-collection kit is adulterated under section 501(f)(1)(B) of the FD&C Act, 21 U.S.C. 351(f)(1)(B) because it does not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C. 360j(g). Your HIV DBS card self-collection kit is also misbranded under section 502(o) the FD&C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the agency, as required by section 510(k) of the FD&C Act, 21 U.S.C. 360(k).\nFDA has not authorized your firm’s HIV DBS card self-collection kit for use in HIV serological diagnostic testing.\nIn a letter dated March 31, 2025, FDA informed you that you appeared to be offering for sale and distributing your HIV serological diagnostic self-collection kits in a manner that may violate the FD&C Act. In your response dated April 30, 2025, you assert that 4U Health “do[es] not sell self-collection testing kits,” and that 4U Health instead “facilitates access to professional medical services, including HIV testing.” You indicate that “[y]our physician consultants order” tests and “oversee the entire testing process.” And you state that the “service” you offer is “not intended to diagnose, treat, or cure any disease on its own,” as “[p]ositive results require confirmation and diagnosis by a licensed medical provider not affiliated with 4U Health.”\nExpress statements on your firm’s website and in your April 30, 2025 response make clear that your firm is selling and distributing HIV serological diagnostic self-collection kits. For example, your website states that the kit “will arrive in plain packaging” and “contains everything you need to collect your home sample.” And your April 30, 2025 response acknowledges that your “at-home testing collection supplies” are “provided to [y]our clients for sample collection.” As explained above, because your firm’s HIV DBS card self-collection kit is a device that has not received FDA marketing authorization, the kit is adulterated and misbranded.\nNotably, this letter and the March 31, 2025 letter sent to your firm focus on your HIV serological diagnostic self-collection kits and are not intended to be a comprehensive list of potential issues with your firm’s products. Even if, as you say, any testing you conduct on samples is intended to provide only preliminary results, the kits you “source[] from independent distributors” and ship to customers for the purpose of sample collection by customers “at-home” (as stated in your April 30, 2025 response) are devices. Nor does the involvement of “physician consultants” in ordering any testing or interpreting any results mean that the collection kits you are shipping are not devices.\nWithout appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your HIV DBS card self-collection kit. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We also note that there are FDA-approved over-the-counter HIV tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your HIV DBS card self-collection kit. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research","4U Health","4u-health-720527-03172026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F4u-health-720527-03172026","2026-10-26T08:07:47.869397+00:00","Closed Out","2026-03-24","720527","Biologics","2026-06-23","Alfred Caminos","2026-08-19T04:50:02.803+00:00","Via UPS and EMAIL","CBER 26-720527","2026-03-17",{"id":99,"raw":100,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":23,"posted_date":113,"marcs_cms_no":114,"product_type":67,"closeout_date":19,"issuing_office":104,"recipient_name":19,"body_fetched_at":115,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":117,"medical_device_id":19,"response_letter_date":19},608,[101,102,103,104,105,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-villas-health-care-llc-dba-villas-health-716504-09092025\">Las Villas Health Care LLC dba Villas Health\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Las Villas Health Care LLC dba Villas Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>401 Coral Way Suite 201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coral Gables\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33134\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:office@villashealth.com\"> office@villashealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Villas Health:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fvillashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.\u003Ca id=\"footnoteref1_f0fiwhc\" href=\"#footnote1_f0fiwhc\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and sildenafil products appear on your website:\u003Cbr>• “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….”\u003Cbr>• “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_f907p23\" href=\"#footnote2_f907p23\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and sildenafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_f0fiwhc\">\u003Ca href=\"#footnoteref1_f0fiwhc\">1\u003C\u002Fa>The semaglutide and sildenafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_f907p23\">\u003Ca href=\"#footnoteref2_f907p23\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nLas Villas Health Care LLC dba Villas Health\n\n401 Coral Way Suite 201\n\nCoral Gables, FL 33134\n\nUnited States\n\noffice@villashealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nVillas Health:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fvillashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.1 As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and sildenafil products appear on your website:\n• “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….”\n• “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and sildenafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The semaglutide and sildenafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Las Villas Health Care LLC dba Villas Health","las-villas-health-care-llc-dba-villas-health-716504-09092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-villas-health-care-llc-dba-villas-health-716504-09092025","2026-10-26T08:09:12.523015+00:00","2025-09-16","716504","2026-08-19T16:23:04.859+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",5,{"510k":120,"classification":121,"enforcement":122,"event":123,"event_backfill":124,"pma":125,"warning_letter":126},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-16T04:00:38.924+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-10T01:03:48.189+00:00"]